MaaT Pharma Completes Recruitment of its ARES Phase 3 Trial for MaaT013 to Treat Acute Graft-versus-Host Disease [fancy-ul icon_type="standard_dash" color="Accent-Color" alignment="left" spacing="default"] Last patient treated in MaaT Pharma’s Phase 3 ARES clinical trial Topline results publication now expected in January 2025 Positive DSMB review of Phase 3 ARES trial announced in Q4 2023, with a [...]
MaaT Pharma to Hold Annual General Meeting on May 28, 2024 Lyon, France, April 22nd 2024 –7.30 am CET – MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotech company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer, informs its shareholders that the [...]
MaaT Pharma Completes Recruitment of its ARES Phase 3 Trial for MaaT013 to Treat Acute Graft-versus-Host Disease [fancy-ul icon_type="standard_dash" color="Accent-Color" alignment="left" spacing="default"] Last patient treated in MaaT Pharma’s Phase 3 ARES clinical trial Topline results publication now expected in January 2025 Positive DSMB review of Phase 3 ARES trial announced in Q4 2023, with a [...] 
